Corpus Intelligence IC Memo — FOUNTAIN VALLEY REG MEDICAL CENTER 2026-04-26 07:37 UTC
IC Memo — FOUNTAIN VALLEY REG MEDICAL CENTER
Investment Committee Memorandum | CA | 400 beds | Grade C | EBITDA uplift $22.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

FOUNTAIN VALLEY REG MEDICAL CENTER

CCN 050570 | ORANGE, CA | 400 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

FOUNTAIN VALLEY REG MEDICAL CENTER is a 400-bed suburban community hospital in ORANGE, CA with $303.4M in net patient revenue and a -12.1% operating margin. The hospital serves a payer mix of 22.4% Medicare, 6.7% Medicaid, and 70.8% commercial.

Thesis: Undervalued. Our ML models identify $22.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -12.1% to -4.7% (+736bps).

Net Revenue HCRIS$303.4M
Current EBITDA COMPUTED$-36.6M
Operating Margin COMPUTED-12.1%
Occupancy HCRIS52.5%
Revenue / Bed COMPUTED$759K
Net-to-Gross HCRIS9.6%
Distress Probability ML47.4%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
145
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -12.1% places it below the state median. Among 145 size-comparable peers (200-800 beds), the median margin is -4.3%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (200-800), prioritizing same-state peers. 145 hospitals in the comp set.

HospitalStateBedsRevenueMargin
FOUNTAIN VALLEY REG MEDICAL CE (Target)CA400$303.4M-12.1%
STANFORD HEALTH CARECA657$6.76B3.7%
UC DAVIS MEDICAL CENTERCA666$3.28B-11.5%
UCSD MEDICAL CENTERCA718$3.06B-7.2%
RONALD REAGAN UCLACA446$2.62B-6.8%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
LOS ANGELES GENERAL MEDICAL CECA596$1.96B10.2%
UCI MEDICAL CENTERCA397$1.90B-2.5%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $22.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$6.4M+210bp18mo
Cost to Collect4.5%2.5%$6.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$6.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$3.7M+122bp9mo
Clean Claim Rate88.0%96.0%$194K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$6.4M
Cost to Collect
$6.1M
Denial Rate Reduction
$6.0M
A/R Days Reduction
$3.7M
Clean Claim Rate
$194K
Total EBITDA Uplift$22.3M
Current EBITDA$-36.6M
+ RCM Uplift+$22.3M
Pro Forma EBITDA$-14.3M
Current Margin-12.1%
Pro Forma Margin-4.7%
WC Released (1x)$11.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-56.4M$-18.3M0.00x-100.0%
Base (11x exit)10.0x11.0x$-56.4M$-38.4M0.00x-100.0%
Bull Case9.0x11.0x$-50.7M$17.0M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-50.7M$3.6M0.00x-100.0%
Bear Case11.0x10.0x$-62.0M$-111.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-62.0M$-142.9M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 145 hospitals with 200-800 beds
  • Same-state prioritization (n=146)
  • Comp margins: P25=-15.8% / P50=-4.3% / P75=3.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.